Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis

Wiener Klinische Wochenschrift

Volumn 127, Issue 11-12, 2015, Pages 427-433

  Esen, Ramazan ^a   Aslan, Mehmet ^a   Kucukoglu, Mehmet Emin ^a   Cıkman, Aytekin ^a   Yakan, Umit ^a   Sunnetcioglu, Mahmut ^a   Selek, Sahbettin ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Acute brucellosis; Oxidative stress index; PON1 activity; Thiol; Total antioxidant capacity; Total oxidant status

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROPEROXIDE; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOL; THIOL GROUP; TRIACYLGLYCEROL; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; OXIDIZING AGENT; PON1 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD SAMPLING; BRUCELLOSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMAGGLUTINATION TEST; HUMAN; LIPID BLOOD LEVEL; MALE; OXIDATIVE STRESS; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; BLOOD; ENZYME ACTIVATION; METABOLISM; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIOMARKERS; BRUCELLOSIS; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFHYDRYL COMPOUNDS;

EID: 84933672152     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-015-0720-z     Document Type: Article

References (55)

1. Ertek M, Yazgı H, Kadanalı A, Özden K, Ta¸syaran MA. Complications of Brucella infection among adults: an 18-year retrospective evaluation. Turk J Med Sci. 2006;36:377–81.
2. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005;352:2325–36.
3. Colmenero JD, Reguera JM, Martos F, et al. Complications associated with brucella melitensis infection: a study of 530 Cases. Medicine (Baltimore). 1996;75:195–211.
4. Gantt KR, Goldman TL, McCormick ML, et al. Oxidative response of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol. 2001;167:893–901.
5. Dieffenbach CW, Tramont EC. Innate (general or nonspecific) host defense mechanisms. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6. ed. Philadelphia: Elsevier Churchill Livingstone; 2005;34–42.
6. Melek IM, Erdogan S, Celik S, Aslantas O, Duman T. Evaluation of oxidative stress and inflammation in long term Brucella melitensis infection. Mol Cell Biochem. 2006;293:203–9.
7. Jiang X, Baldwin CL. Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide. Cell Immunol. 1993;151:309–19.
8. Serefhanoglu K, Taskin A, Turan H, Timurkaynak FE, Arslan H, Erel O. Evaluation of oxidative status in patients with brucellosis. Braz J Infect Dis. 2009;13(4):249–51.
9. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871–9.
10. Kosaka T, Yamaguchi M, Motomura T, Mizuno K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta. 2005;359:156–62.
11. Ng CJ, Shih DM, Hama SY, Villa N, NavabM, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radical Biol Med. 2005;38:153–63.
12. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knock out mice. Free Radical Biol Med. 2003;34:774–84.
13. Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem. 2008;41:1067–73.
14. Kabaroglu C, Mutaf I, Boydak B, et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol. 2004;59(6):606–11.
15. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res. 2003;44:780–92.
16. Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet’s disease. Br J Ophthalmol. 2004;88:1256–8.
17. Demirpence O, Sevim B, Yıldırım M, Ayan Nurlu N, Mert D, Evliyaoglu O. Serum paraoxonase, TAS, TOS and ceruloplasmin in brucellosis. Int J Clin Exp Med. 2014;7(6):1592–7.
18. Apostolou F, Gazi IF, Kostoula A, et al. Persistence of an atherogenic lipid profile after treatment of acute infection with brucella. J Lipid Res. 2009;50:2532–9.
19. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radicalcation. Clin Biochem. 2004;37:277–85.
20. Sodergren E, Nourooz-Zadeh J, Berglund L, Vessby B. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. J Biochem Biophys Methods. 1998;37(3):137–46.
21. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–9.
22. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–11.
23. Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O. Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis. 2005;5:95–101.
24. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–38.
25. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C. 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem. 1992;30:391–5.
26. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999;300:58–62.
27. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994;233:381–5.
28. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6. ed. Philadelphia: Elsevier Churchill Livingstone; 2005;2669–74.
29. Niemela S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 1996;75:573–5.
30. Hoffmeister A, Rothenbacher D, Bode G, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol. 2001;21:427–32.
31. Altintas E, Ucbilek E, Ulu O, Sezgin O, Uzer C. Helicobacter pylori associated atrophic gastritis and carotid intima-media thickness, is there a link? Int Clin Pract. 2007;61(5):810–4.
32. Van Leeuwen, HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359–66.
33. Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis. 2008;196:270–4.
34. Mackness B, Mackness MI, Arrol S, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341–9.
35. Quemeneur T, Martin-Nizard F, Kandoussi A, et al. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Semin Arthritis Rheum. 2007;37:149–55.
36. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193–9.
37. Rizzo M, Kotur-Stevuljevic J, Berneis K, Spasojevic- Kalimanovska V, Vekic J. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res. 2009;153:217–23.
38. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705–12.
39. La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact. 1999;119–120:379–88.
40. Ali EM, Shehata HH, Ali-Labib R, Esmail Zahra LM. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. Clin Biochem. 2009;42:1394–1400.
41. Ates O, Azizi S, Alp HH, Kiziltunc A, Kocer I, Baykal O. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med. 2009;217:17–22.
42. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol. 2005;11:7351–4.
43. Parra S, Alonso-Villaverde C, Coll B, et al. Serum paraoxonase-1 activity and concentration are infl uenced by human immunodefi ciency virus infection. Atherosclerosis. 2007;194:175–81.
44. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol Med. 1999;26:892–904.
45. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813–8.
46. Mackness B, Durington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the caterphilly prospective study. Circulation. 2003;107:2775–9.
47. Sutherland WHF, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after meal rich in used cooking fat. Arterioscler Thromb Vasc Biol. 1999;19:1340–7.
48. Van der Gaag MS, van Tol A, Scheek LM, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet controlled, randomized intervention study in middle-aged men. Atherosclerosis. 1999;147:405–10.
49. Chandra M, Chandra N, Agrawal R, Kumar A, Ghatak A, Pandey VC. The free radical system in ischemic heart disease. Int J Cardiol. 1994;43:121–5.
50. Jarvik GP, Tsai NT, McKinstry LA, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol. 2004;22:1329–33.
51. Kakafika AI, Xenofontos S, Tsimihodimos V, et al. The PON1 M55 L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res. 2003;44:1919–26.
52. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patientswith iron deficiency anemia. Atherosclerosis. 2007;191:397–402.
53. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003;81(12):766–79.
54. Sepahvand F, Shafiei M, Ghaffari SM, Rahimi-Moghaddam P, Mahmoudian M. Paraoxonase phenotype distribution in a healthy Iranian population. Basic Clin Pharmacol Toxicol. 2007;101:104–7.
55. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol. 2001;21:1451–7.